[gdpawel]

Vancouver, B.C. June 11th, 2012 – biOasis Technologies Inc. announced that research underway at Texas Tech University Health Sciences Center has yielded some compelling data on preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of Transcend and Herceptin) in animal models of breast cancer metastasis to the brain.

The studies were conducted for biOasis under the direction of Drs. Quentin Smith and Paul Lockman, both recognized experts on the Blood-Brain Barrier and in evaluating drug delivery to the central nervous system for the treatment of brain tumors. The data showed that 6.6% of the injected dose of BT2111 penetrated the Blood-Brain Barrier and entered brain tissue.

This is consistent with previous studies showing that Transcend can effectively deliver several types of different compounds to the brain. The rate of BT2111 uptake into the brain was 1000-fold greater than Herceptin on its own. BT2111 was clearly present in the metastatic breast cancer tumors as determined by measurement of radioactive molecules using phosphorescence imaging of normal brain and brain metastases.

The uptake of BT2111 into the brain was similar to that observed for the Transcend vector alone, supporting previous observations that Transcend can effectively carry large biologics across the Blood-Brain Barrier. The next steps at Texas Tech University are to complete the study plan to show that the delivery of BT2111 into the brain has a therapeutic effect on metastatic breast cancer.

BT2111 is a conjugate between biOasis’ Transcend brain delivery vector and trastuzumab (trade name Herceptin), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood- brain barrier, biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain.

biOasis Technologies Inc. is a biopharmaceutical company in Vancouver, Canada. Based on Transcend, a proprietary brain delivery platform of biOasis, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases.